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Abstract: The advances in recombinant DNA technology have led to an improvement in the properties of currently available longacting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a
promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of
hypoglycemic events in both type 1 and type 2 diabetic patients has been demonstrated.1,2 Its unique mechanism of action is based on
multihexamer formation after subcutaneous injection. This reportedly allows for less pharmacodynamic variability and within-subject
variability than currently available insulin analogs, and a duration of action that is over 24 hours.3 The lack of proof of carcinogenicity
with insulin degludec is yet another factor that would be taken into consideration when choosing the optimal basal insulin for a diabetic
individual.4 A formulation of insulin degludec with insulin aspart, Insulin degludec 70%/aspart 30%, may permit improved flexibly of
dosing without compromising glycemic control or safety.5
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Introduction

Pancreatic beta cells release insulin continuously
between meals at a near constant rate and in the fasting state. This basal insulin secretion acts to restrain
the release of glucose from the liver and free fatty
acids from the adipose tissue in order to prevent
hyperglycemia and ketosis. The development of insulin analogs, in effort to produce safer insulin formulations that would closely mimic the basal and mealtime
components of endogenous insulin secretion, allowed
for more flexible treatment regimens with a lower
risk of development of hypoglycemia. Insulin analogs, created via recombinant DNA technology, are
modified versions of human insulin that primarily
alter the duration of absorption of the molecule. An
improvement in the properties of currently available
long-acting insulin analogs has been achieved with
the new generation long-acting basal insulin analog,
insulin degludec. Clinical trials have demonstrated
a longer duration of action and lower incidence of
hypoglycemic events in both type 1 and type 2 diabetic patients using insulin degludec.1,2 This article
reviews currently available information about insulin degludec, in comparison to the other basal insulin
analogs (Table 1 and Fig. 1).

Mechanism of Action, Metabolism
and Pharmacokinetic Profile

Insulin degludec is a neutral, soluble ultra-long-acting
insulin that forms large multihexamer assemblies at
physiological pH following subcutaneous injection.
Its molecular structure is similar to the human insulin
amino acid sequence, apart from deletion of Threonine
at position B30 and the addition of a 16-carbon fatty
diacid attached to Lysine at position B29 via a glutamic
acid spacer (Fig. 1). This conformation allows insulin

degludec to exist as dihexamers in solution which form
multihexamers after subcutaneous injection.3 According to the manufacturer, Novo Nordisk, the large
molecular size allows for continuous slow release of
degludec monomers with reportedly less pharmacodynamic variability and within-subject variability than
currently available insulin analogs, and a duration of
action that is over 24 hours. Its metabolism is mainly
via the kidneys. The contribution of renal metabolism
is enhanced as exogenous insulin bypasses the liver.3,6
A study involving 12 type 1 diabetic subjects has
shown that insulin degludec had a half life longer than
24 hours and was found to be detectable in the circulation for at least 96 hours after injection; however,
it is unknown whether or not it is still biologically
active at that time. Insulin receptor binding studies
and in vitro studies have indicated that insulin degludec is comparable to human insulin in its low affinity
for the human insulin-like growth factor-1 receptor,
with a similar low mitogenic/metabolic potency ratio
and, therefore, no proof of carcinogenicity.4,6–8

Clinical Studies
Phase 2 trials

Three phase 2 trials comparing insulin degludec with
insulin glargine have been conducted. All were openlabel, randomized, parallel-group, treat-to-target trials
and had a duration of 16-weeks.
A trial including type 1 diabetes patients showed
no differences in hemoglobin A1c, fasting plasma glucose, and mean total daily dose between insulin degludec once a day with insulin glargine once a day, both
combined with insulin aspart. There was a difference
in the rate of confirmed hypoglycemia and especially
confirmed nocturnal hypoglycemia between insulin
degludec once a day and insulin glargine once a day.

Table 1. Comparison of insulin degludec and other insulin analogs.
Basal insulin

Onset

Peak

Duration

Comments

NPH
Glargine

1–2 hours
30–60 minutes

4–8 hours
No peak

8–12 hours
16–24 hours

Detemir
Degludec

30–60 minutes
30–90 minutes

No peak
No peak

16–24 hours
Over 24 hours

Degludec plus

5–15 minutes

30–60 minutes

Over 24 hours

Greatest risk for hypoglycemia
– Greatest potential for weight gain.
– Possible mitogenicity
May need twice daily injections.
– Least risk of hypoglycemia
– No mitogenicity
Same as degludec with advantage
of added prandial coverage.

Abbreviation: NPH, neutral protamine hagedorn.
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Figure 1. Molecular structure of long-acting insulin analogs: (A) insulin glargine, (B) insulin detemir, and (C) insulin degludec.

The rates of overall and nocturnal hypoglycemia of
insulin degludec and insulin glargine and the risk
reductions compared with glargine were 47.9 and
66.2 events/patient-year (relative risk 0.72) and 5.1
and 12.3 events/patient-year (relative risk 0.42), both
in favor of insulin degludec once a day.1,9–11
A study among diabetes type 2 patients tested
insulin degludec in either a once per day regimen or a
three-times weekly regimen, compared against insulin glargine. All efficacy outcome measures, including
the mean weekly insulin dose, were similar compared
with each other and compared with insulin glargine.
This study among type 2 diabetes patients, found no
significant differences in the rate of confirmed hypoglycemic events among degludec once a day, degludec three-times weekly, and insulin glargine once a
day. Although hypoglycemic events occurred less
with degludec once a day, they occurred more in the
degludec three-times weekly treatment group.1,2,12
Therefore, its manufacturer, Novo Nordisk, is seeking FDA approval for once a day clinical use.
A third study investigated a Insulin degludec Plus
co-formulation, comprising 70% insulin degludec and
30% insulin aspart in type 2 diabetes patients dosed
at dinnertime. There was no difference in hemoglobin
A1c and fasting plasma glucose compared with insulin glargine once a day.
Two outcome measures were in favor of Insulin
degludec Plus compared with insulin glargine: Insulin
degludec Plus had a 27 mg/dL lower mean 2-h postdinner plasma glucose and a 7 U/kg lower mean daily
Clinical Medicine Insights: Endocrinology and Diabetes 2012:5

insulin dose. The rate of confirmed hypoglycemic
events and nocturnal hypoglycemic events was low
for both Insulin degludec Plus and insulin glargine,
without significant differences between them.1,13,14
This co formulation is a promising treatment option for
initiating insulin therapy in subjects with type 2 diabetes inadequately controlled with oral anti-diabetic
agents. The phase 2 trial also investigated the use of
a second formulation of insulin degludec 55%/Aspart
45%, which was associated with a twofold higher rate
of confirmed, mostly nocturnal, hypoglycemia which
discontinued its clinical development.13
In a proof-of-concept trial comparing Insulin
degludec/aspart with biphasic insulin aspart 30 (30%
soluble, rapid-acting insulin aspart and 70% protaminebound insulin aspart), Insulin degludec/aspart was
associated with a significantly lower fasting plasma
glucose and a significantly lower rate of confirmed
hypoglycemia than biphasic insulin aspart 30.15

Phase 3 studies

12 phase 3 trials are registered at www.ClinicalTrials.
gov aiming to assess the efficacy and safety of insulin
degludec, including approximately 7,000 participants,
and all studies have been completed. Preliminary
results of the phase 3 trials showed that there were
no differences in A1c between Insulin degludec once
a day and Insulin glargine, although Insulin degludec
was not non-inferior regarding A1c when administered three-times weekly in patients with type 2 diabetes, resulting in discontinuation of the three-times
33
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weekly dosing option. In the once a day dosing option,
a reduction in nocturnal hypoglycemia was seen in
a 52-week trial, together with a significantly lower
fasting plasma glucose level. In one study, insulin
degludec given as basal-bolus treatment with insulin aspart in people with type 2 diabetes, improved
long-term glycemic control with significantly lower
risk of overall and nocturnal hypoglycemia compared
with insulin glargine. In patients with type 1 diabetes,
Insulin degludec once a day reduced the risk of nocturnal hypoglycemia compared with Insulin glargine
once a day.1,16 In another phase 3 trial, the efficacy
and safety of Insulin degludec/aspart used once daily
at any meal with insulin aspart at the remaining meals
in type 1 diabetics, provided similar glycemic control
to insulin detemir with mealtime insulin aspart. The
Insulin degludec/aspart regimen was associated with
significantly less nocturnal hypoglycemia, and had
the added convenience of fewer daily injections than
conventional basal-bolus therapy.17

Safety

Insulin degludec used alone is associated with less
pharmacodynamic and within-subject variability
than insulin glargine, with a lower chance of inducing hypoglycemia, in both type 1 and type 2 diabetic
patients.2,9,18 The rates of hypoglycemia and nocturnal hypoglycemia, in insulin-naïve people with type
2 diabetes, were similar between insulin degludec
70%/insulin aspart 30% and insulin glargine. This
lower risk of inducing hypoglycemia, in particular
nocturnal hypoglycemia, might be a major factor in
choosing a regimen to that targets optimal glycemic
control, especially in patients with blunted hypoglycemic awareness.
In studies involving the binding affinity of insulin
degludec to IGF-1 receptors, the affinity of insulin
degludec for the human IGF-1 receptor was found
to be low, with a molecular safety that is similar to
human insulin. This has omitted any proof of carcinogenicity with insulin degludec, in comparison to
concerns regarding possible metabolic and mitogenic
potencies of insulin glargine.4

Efficacy

The continuous, slow, stable release of insulin degludec monomers provides a smooth and stable exposure for more than 24 hours, with less variability and
34

a more stable glucose-lowering effect than insulin
glargine.9,19,20 Insulin degludec 70%/aspart 30% has
the added advantage of a lower mean 2-h post-dinner
plasma glucose increment and lower mean daily insulin dose when compared to insulin glargine.1,13 In one
trial, it was shown that insulin degludec can be dosed
flexibly at any time of the day so that injection times
can be changed from day to day without compromising glycemic control or safety compared to insulin
glargine dosed at the same day.5

Patient Preference

Based on the long duration of action and lower events
of hypoglycemia and unproven carcinogenicity, the
main determinant of patient preference will probably
be the cost of insulin degludec given once a day.

Place in Therapy

Insulin degludec has a high potential for use as an
ultra-long acting basal insulin in both the ambulatory
and inpatient setting, with a more favorable profile
compared to the other basal insulins currently in use.
One possible disadvantage in its use in the hospital setting, due to its prolonged effect of more than
24 hours, is the decreased ability to make day-to-day
adjustments in the basal insulin dose, in order to optimize blood sugar control. This potential risk may be
more pronounced in patients with renal or hepatic
impairment. The long acting analogs currently in use,
glargine and detemir, both allow for adjustments on
a daily basis or shorter period, in advent of hypoglycemia or hyperglycemia.8,13 However, newer clinical
studies have shown that the soluble insulin combination of an ultra-long-acting basal insulin degludec and
rapid-acting insulin, insulin aspart, provides fasting
plasma glucose control with significantly less hypoglycemia compared to biphasic insulin aspart.21

Discussion

The introduction of insulin analogs has revolutionized
glycemic control, through administration of basal and
prandial insulin with or without “correction dose”
insulin, which in turn approximates physiologic insulin demand. Insulin Lispro was the first rapid acting
insulin analog, created by inversion of the lysine of
B29 and the proline of B28 of human insulin, causing a conformational change that results in a shift in
the normal binding of the C-terminal portion of the B
Clinical Medicine Insights: Endocrinology and Diabetes 2012:5
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chain, which in turn reduces the formation of dimers
and hexamers. In contrast, the concept behind insulin
degludec, is multihexamer formation at the subcutaneous injection site which prolongs its duration of
action. This mechanism of action differs from insulin
degludec’s predecessors, insulin glargine, which was
introduced in 2001, and insulin detemir (Table 1).
Insulin glargine is produced by the substitution of
glycine for asparagine at position A21 of the insulin
molecule and by the addition of two arginine molecules at position B30 (Fig. 1). These changes lead
to a shift in the isoelectric point toward a neutral
pH, which results in an insulin molecule that is less
soluble at the injection site and that precipitates in
the subcutaneous tissue to form a depot from which
insulin is slowly released.7,22 Insulin detemir is an
acylated derivative of human insulin which binds to
albumin through a fatty-acid chain attached to the
lysine at residue B29, leading to a reduction in free
detemir levels (Fig. 1).
In both type 1 and 2 diabetics, the main advantage with the use of insulin glargine instead of neutral
protamine hagedorn insulin “NPH”, has been a reduction in the risk of hypoglycemia, especially nocturnal
hypoglycemia.22 In type 2 diabetics, insulin glargine
is comparable with NPH insulin, insulin detemir and
exenatide in reducing A1c levels. Disadvantages of
insulin glargine include weight gain versus weight
loss with GLP-1 agonists and more effective A1c
reduction with biphasic insulins if insulin glargine
is not combined with prandial coverage.23 A recent
meta-analysis comparing the efficacy and safety of
long-acting insulin analogs in patients with type 2
diabetes failing on oral therapy, demonstrated that initiating long-acting insulin analogs seems to provide
glycemic control similar to rapid-acting insulin analogs or NPH insulin or glucagon-like peptide-1 analogs and slightly inferior to biphasic insulin analogs
with fewer side-effects.22,24 Insulin detemir has less
variability in absorption than does NPH, a feature
associated with a reduced risk of hypoglycemia which
may contribute to less weight gain (Table 1). Insulin
detemir appears to have a shorter time–action profile
at lower doses, compared with insulin glargine, which
may require twice-daily injections in persons with
type 1 diabetes.22,25 A recent analyses suggested that
there is no clinically relevant difference in efficacy or
safety between insulin detemir and insulin glargine for
Clinical Medicine Insights: Endocrinology and Diabetes 2012:5

targeting hyperglycemia. However, to achieve the same
glycemic control insulin detemir was often injected
twice-daily in a higher dose but with less weight gain,
while insulin glargine was injected once-daily, with
somewhat fewer injection site reactions. As with insulin glargine, similar advantages with insulin detemir
include lower incidence of hypoglycemia compared
with NPH and biphasic insulins23 (Table 1).
With insulin degludec having less pharmacodynamic and within-subject variability than insulin
glargine and detemir, there is a reduced chance of
inducing hypoglycemia, in both type 1 and type 2
diabetic patients. Similar rates of hypoglycemia and
nocturnal hypoglycemia, in insulin-naïve people with
type 2 diabetes have been shown with insulin degludec 70%/insulin aspart 30% and insulin glargine.2,9,18
There have been concerns of the metabolic and
mitogenic potencies of insulin glargine, due to IGF-1
—receptor binding and demonstration of an increase in
both IGF-1—receptor affinity and mitogenic potency
in a cell-culture model that used human osteosarcoma
cells. This was implicated in the possible development
of mammary, ovarian, and bone tumors in addition
to the development of diabetic retinopathy. Due to
these suspicions, it has been considered unwise to use
insulin glargine in pregnancy.22,25 Newer data, from a
large population-based follow-up study, showed that
insulin glargine and users of other insulin analogs
had a lower risk of cancer in general than those using
human insulin; however, an increased risk of breast
cancer was seen in users of insulin glargine in comparison with users of human insulin.26 In a more recent
cohort study involving only type 2 diabetic patients,
the previous findings of an increased risk of cancer
with insulin glargine compared with human insulin
was not confirmed, and an increased risk of all-cause
death with human insulin was found when compared
with insulin glargine.27 With insulin degludec, since
its affinity for the human IGF-1 receptor is low, the
molecular safety is similar to human insulin, with no
proof of carcinogenicity (Table 1).4

Conclusions

The new ultra-long basal insulin degludec , which is
currently still undergoing phase 3 trials, may be an
attractive therapeutic alternative to the other basal
insulins, due to less pharmacodynamic variability,
a longer duration of action, less potential for
35
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h ypoglycemic events and lower theoretical mitogenic
potential. Its developer, Novo Nordisk, has filed for
regulatory approval but at this writing it still awaits
approval in Europe and the US for clinical use.
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